Glen Rock, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, and ResolutionRx Ltd (“ResolutionRx”), an unlisted public Australian company, (Australian Company Number or ACN: 664 925 651) and a subsidiary of RespireRx, are pleased to announce that on October 9, 2023, ResolutionRx entered into a Master Services Agreement (“MSA”) with Ab Initio Pharma Pty Ltd, (“Ab Initio”) an Australian company under which Ab Initio will manufacture, formulate, test and supply ResolutionRx with therapeutic drugs based on lipid nanoparticle technology licensed from RespireRx.

Glen Rock，N.J.，2023年10月12日（GLOBE NEWSWIRE）-RespireRx Pharmaceuticals Inc.（OTC粉红色市场：RSPI）（“RespireRx”或“公司”），专注于发现和开发创新和革命性的治疗方法，以对抗由神经信号中断引起的疾病，以及ResolutionRx Ltd（“ResolutionRx”），一家未上市的澳大利亚上市公司，（澳大利亚公司编号或ACN:664 925 651）和RespireRx的子公司很高兴地宣布，2023年10月9日，ResolutionRx与Ab Initio Pharma Pty Ltd签订了主服务协议（“MSA”）（“Ab Initio”）一家澳大利亚公司，根据该公司，Ab Initio将制造，制定，使用基于RespireRx许可的脂质纳米颗粒技术的治疗药物测试和供应分辨率Rx。

The initial services relate to ResolutionRx’s repurposing of dronabinol and its development program for obstructive sleep apnea pursuant to which Ab Initio will, among other things, manufacture and test our new dronabinol lipid nanoparticle formulation for pharmacokinetic, pharmacodynamic, and pivotal clinical trials, as well as ultimately for commercialization.

最初的服务涉及ResolutionRx对屈大麻酚的再利用及其阻塞性睡眠呼吸暂停的开发计划，其中从头开始将制造和测试我们的新屈大麻酚脂质纳米颗粒制剂用于药代动力学，药效学和关键临床试验，以及最终实现商业化。

The initial term of the MSA is two years and automatically renews for one-year periods unless ResolutionRx provides written notice to Ab Initio of its intent not to renew at least ninety days prior to the end of the initial term or any renewal term. “The importance of this partnership cannot be overstated,” said Arnold Lippa, Ph.D., co-CEO and CSO of ResolutionRx and CEO and CSO of RespireRx.

MSA的初始期限为两年，并自动续签一年，除非ResolutionRx从头开始书面通知其意图不在初始期限结束前至少九十天或任何续签期限之前续签。ResolutionRx的联合首席执行官和CSO以及RespireRx的首席执行官和CSO的Arnold Lippa博士说：“这种合作关系的重要性怎么强调都不为过。”。

“With its formulation expertise and GMP manufacturing facilities, Ab Initio will complete our original laboratory experiments to determine a final, optimum dronabinol formulation, scale up and manufacture the chosen formulation for clinical use. The .

“凭借其配方专业知识和GMP生产设施，Ab Initio将完成我们最初的实验室实验，以确定最终的最佳屈大麻酚配方，扩大规模并制造用于临床的所选配方。